13F 申报指南13F 概念全攻略
什么是 SEC Form 13F 申报？美股机构大户持股全攻略
完整解读 Form 13F 申报规范、1 亿美元门槛与 45 天延迟申报机制，学会如何追踪顶级对冲基金与机构法人持仓动向。
AlphaSMO 权威研究指南阅读专题
CIK: 0001773195
申报总市值
US$22.1亿
US$22.1亿
103 檔
22.6%
在 Q1 2026 的 13F 官方备案中，Affinity Asset Advisors, LLC 管理的美股投资组合规模来到 US$22.1亿，整体持股档数为 103 档。
在 Q1 2026，Affinity Asset Advisors, LLC 操作展现出积极扩展与加仓意向。本季共新建仓 26 个新仓位，并对 31 个既有持股进行加仓（合计增持 57 档），相较减仓与清仓仓位显著占优。
在资产配置集中度方面，Affinity Asset Advisors, LLC 的前 5 大核心持股（包含 SPY, APGE, XENE 等）合计占整体申报市值的 22.6%，反映机构在主要关键仓位上的权重分布。
| # | 代码 | 标的名称 | 资产子类别 | 占比 | 占比变动 | 持仓量变化 | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-大型股与成长 | 6.72% | -6.72% | EXIT | |
| 2 | APGE | Apogee Therapeutics Inc | 股票-其他 | 5.59% | +0.33% | +4.05% | |
| 3 | XENE | Xenon Pharmaceuticals Inc | 股票-其他 | 5.03% | -0.68% | +34.00% | |
| 4 | ERAS | Erasca Inc | 股票-其他 | 4.47% | -0.12% | +37.18% | |
| 5 | INSM | Insmed Inc | 股票-医疗保健 | 4.05% | -0.92% | +6.67% | |
| 6 | ROIV | Roivant Sciences Ltd. | 股票-医疗保健 | 4.01% | +1.99% | +64.71% | |
| 7 | SYRE | Spyre Therapeutics Inc | 股票-其他 | 3.33% | +1.80% | -10.71% | |
| 8 | 260 | Centessa Pharmaceuticals-adr | 股票-其他 | 2.87% | -2.87% | EXIT | |
| 9 | PRAX | Praxis Precision Medicines I | 股票-其他 | 2.83% | -0.03% | -8.11% | |
| 10 | ANAB | Anaptysbio Inc | 股票-其他 | 2.69% | -0.17% | +111.38% | |
| 11 | ALKS | Alkermes plc | 股票-医疗保健 | 2.47% | +0.79% | +35.00% | |
| 12 | CYTK | Cytokinetics Inc | 股票-医疗保健 | 2.38% | -0.26% | -12.44% | |
| 13 | ABVX | Abivax Sa-adr | 股票-其他 | 2.33% | -0.34% | -19.80% | |
| 14 | TEVA | Teva Pharmaceutical-sp Adr | 股票-医疗保健 | 2.18% | -1.61% | — | |
| 15 | ACLXGBX | Arcellx Inc | 股票-其他 | 2.15% | -2.15% | EXIT | |
| 16 | MRNA | Moderna Inc | 股票-医疗保健 | 2.10% | +0.99% | — | |
| 17 | DNTH | Dianthus Therapeutics Inc | 股票-其他 | 1.73% | +0.03% | +247.83% | |
| 18 | NUVL | Nuvalent Inc-a | 股票-其他 | 1.59% | -0.05% | -7.02% | |
| 19 | 430 | Terns Pharmaceuticals Inc | 股票-其他 | 1.53% | -1.53% | EXIT | |
| 20 | LXEO | Lexeo Therapeutics Inc | 股票-其他 | 1.50% | -0.28% | +57.82% | |
| 21 | COGT | Cogent Biosciences Inc | 股票-其他 | 1.49% | -0.70% | +114.29% | |
| 22 | MDGL | Madrigal Pharmaceuticals Inc | 股票-医疗保健 | 1.49% | -0.52% | +76.67% | |
| 23 | STRO | Sutro Biopharma Inc | 股票-其他 | 1.38% | +0.38% | +42.91% | |
| 24 | FBRX | Forte Biosciences Inc | 股票-其他 | 1.35% | -0.25% | — | |
| 25 | ORKA | Oruka Therapeutics Inc | 股票-其他 | 1.27% | +1.27% | -37.72% | |
| 26 | TRVI | Trevi Therapeutics Inc | 股票-其他 | 1.23% | +0.29% | -6.98% | |
| 27 | OVID | Ovid Therapeutics Inc | 股票-其他 | 1.22% | +0.01% | +48.76% | |
| 28 | ELVN | Enliven Therapeutics Inc | 股票-其他 | 1.19% | -0.04% | — | |
| 29 | ASND | Ascendis Pharma A/S | 股票-其他 | 1.12% | -1.12% | EXIT | |
| 30 | MLYS | Mineralys Therapeutics Inc | 股票-其他 | 1.05% | -0.14% | +2.74% | |
| 31 | AVTX | Avalo Therapeutics Inc | 股票-其他 | 1.03% | +1.39% | +27.57% | |
| 32 | RVMD | Revolution Medicines Inc | 股票-医疗保健 | 1.00% | +1.12% | +100.00% | |
| 33 | BMY | Bristol-myers Squibb Co | 股票-医疗保健 | 0.94% | -0.94% | EXIT | |
| 34 | PTGX | Protagonist Therapeutics Inc | 股票-其他 | 0.94% | +0.01% | — | |
| 35 | CLDX | Celldex Therapeutics Inc | 股票-其他 | 0.82% | +0.36% | +42.86% | |
| 36 | ✓ | Zura Bio LTD | 股票-其他 | 0.79% | -0.40% | +41.39% | |
| 37 | NRIX | Nurix Therapeutics Inc | 股票-其他 | 0.77% | +0.29% | — | |
| 38 | SVRA | Savara Inc | 股票-其他 | 0.71% | -0.01% | -10.19% | |
| 39 | OMER 9.5 06-15-29债券 | Omeros CORP | 债券 | 0.68% | -0.13% | — | |
| 40 | CATX | Perspective Therapeutics Inc | 股票-其他 | 0.68% | -0.03% | +954.86% | |
| 41 | ✓ | Helix Acquisition CORP Iii | 股票-其他 | 0.66% | -0.06% | — | |
| 42 | ARWR | Arrowhead Pharmaceuticals In | 股票-医疗保健 | 0.65% | -0.10% | +185.71% | |
| 43 | DMRA | Damora Therapeutics Inc | 股票-其他 | 0.60% | -0.10% | — | |
| 44 | EPRX | Eupraxia Pharmaceuticals Inc | 股票-其他 | 0.59% | -0.10% | +429.67% | |
| 45 | ANRO | Alto Neuroscience Inc | 股票-其他 | 0.58% | +0.43% | — | |
| 46 | BBIO | Bridgebio Pharma Inc | 股票-医疗保健 | 0.58% | -0.58% | EXIT | |
| 47 | CGEM | Cullinan Therapeutics Inc | 股票-其他 | 0.57% | +0.15% | -59.56% | |
| 48 | BLTE | Belite Bio Inc - Adr | 股票-其他 | 0.54% | +0.61% | +225.00% | |
| 49 | WVE | Wave Life Sciences Ltd. | 股票-其他 | 0.52% | -0.52% | EXIT | |
| 50 | VERA | Vera Therapeutics Inc | 股票-其他 | 0.52% | -0.04% | — |
| # | 代码 | 标的名称 | 占比变动 | 持仓量变化 | 异动类型 |
|---|---|---|---|---|---|
| 1 | ERAS | Erasca Inc | +3.6% | +37.18% | 加仓 |
| 2 | 260 | Centessa Pharmaceuticals-adr | +2% | +133.12% | 加仓 |
| 3 | ROIV | Roivant Sciences Ltd. | +1.9% | +64.71% | 加仓 |
| 4 | XENE | Xenon Pharmaceuticals Inc | +1.8% | +34.00% | 加仓 |
| 5 | ANAB | Anaptysbio Inc | +1.5% | +111.38% | 加仓 |
| 6 | DNTH | Dianthus Therapeutics Inc | +1.5% | +247.83% | 加仓 |
| 7 | STRO | Sutro Biopharma Inc | +0.9% | +42.91% | 加仓 |
| 8 | ALKS | Alkermes plc | +0.9% | +35.00% | 加仓 |
| 9 | COGT | Cogent Biosciences Inc | +0.8% | +114.29% | 加仓 |
| 10 | ASND | Ascendis Pharma A/S | +0.8% | +216.67% | 加仓 |
| 11 | SYRE | Spyre Therapeutics Inc | +0.7% | -10.71% | 减仓 |
| 12 | CATX | Perspective Therapeutics Inc | +0.6% | +954.86% | 加仓 |
| 13 | OVID | Ovid Therapeutics Inc | +0.6% | +48.76% | 加仓 |
| 14 | RVMD | Revolution Medicines Inc | +0.6% | +100.00% | 加仓 |
| 15 | MDGL | Madrigal Pharmaceuticals Inc | +0.5% | +76.67% | 加仓 |
| 16 | EPRX | Eupraxia Pharmaceuticals Inc | +0.5% | +429.67% | 加仓 |
| 17 | ARWR | Arrowhead Pharmaceuticals In | +0.4% | +185.71% | 加仓 |
| 18 | COGT 1.625 11-15-31债券 | Cogent Biosciences Inc | +0.4% | +600.00% | 加仓 |
| 19 | BLTE | Belite Bio Inc - Adr | +0.4% | +225.00% | 加仓 |
| 20 | APGE | Apogee Therapeutics Inc | +0.3% | +4.05% | 加仓 |
| 21 | CLDX | Celldex Therapeutics Inc | +0.3% | +42.86% | 加仓 |
| 22 | 430 | Terns Pharmaceuticals Inc | +0.3% | +2.30% | 加仓 |
| 23 | ✓ | Zura Bio LTD | +0.3% | +41.39% | 加仓 |
| 24 | CMPS | Compass Pathways PLC | +0.2% | +454.24% | 加仓 |
| 25 | ACLXGBX | Arcellx Inc | +0.2% | -30.73% | 减仓 |
| 26 | AVR | Anteris Technologies Global | +0.1% | +87.47% | 加仓 |
| 27 | PTGX | Protagonist Therapeutics Inc | +0.1% | — | 不变 |
| 28 | IBIO | Ibio Inc | +0.1% | +51.04% | 加仓 |
| 29 | AVBP | Arrivent Biopharma Inc | 0% | +16.67% | 加仓 |
| 30 | MGNX | Macrogenics Inc | 0% | +3.24% | 加仓 |
| 31 | CELC 2.75 08-01-31债券 | Celcuity Inc | 0% | — | 不变 |
| 32 | 2KZ0 | Kezar Life Sciences Inc | 0% | — | 不变 |
| 33 | QTTB | Q32 Bio Inc | — | — | 不变 |
| 34 | XFOR | X4 Pharmaceuticals Inc | — | — | 不变 |
| 35 | ADGM | Adagio Medical Holdings Inc | — | — | 不变 |
| 36 | RCKTW | Rocket Pharmaceuticals In-27 | — | — | 不变 |
| 37 | ✓ | 0% | — | 不变 | |
| 38 | LENZ | Lenz Therapeutics Inc | 0% | — | 不变 |
| 39 | OBIO | Orchestra Biomed Holdings In | -0.1% | -29.72% | 减仓 |
| 40 | CLYM | Climb Bio Inc | -0.1% | -46.15% | 减仓 |
| 41 | AVTX | Avalo Therapeutics Inc | -0.1% | +27.57% | 加仓 |
| 42 | CRNX | Crinetics Pharmaceuticals In | -0.1% | — | 不变 |
| 43 | ✓ | Proqr Therapeutics N.v. | -0.1% | — | 不变 |
| 44 | NXTC | Nextcure Inc | -0.1% | -2.21% | 减仓 |
| 45 | ✓ | Newamsterdam Pharma Company | -0.1% | — | 不变 |
| 46 | RZLT | Rezolute Inc | -0.1% | -34.17% | 减仓 |
| 47 | NAMS | NewAmsterdam Pharma Company N.V. | -0.1% | — | 不变 |
| 48 | ✓ | Engene Holdings Inc | -0.1% | -5.13% | 减仓 |
| 49 | ORKA | Oruka Therapeutics Inc | -0.1% | -37.72% | 减仓 |
| 50 | VRCA | Verrica Pharmaceuticals Inc | -0.1% | — | 不变 |
根据 SEC 官方 Form 13F 申报备案，Affinity Asset Advisors, LLC 在 Q1 2026 季度的美股持仓总市值约为 US$22.1亿，共申报了 103 个公开持股仓位。
在 Q1 2026 季度，Affinity Asset Advisors, LLC 按市值排列的前三大核心持股分别为：SPY (6.7%)、APGE (5.6%)、XENE (5.0%)。其中最大持股仓位 SPY 占据整体投资组合约 6.7% 的权重。
精选 AlphaSMO 大户持股与内部人交易深度分析，提升投资决策胜率
完整解读 Form 13F 申报规范、1 亿美元门槛与 45 天延迟申报机制，学会如何追踪顶级对冲基金与机构法人持仓动向。
本季最大新建仓标的
SPY
市值: US$1.3亿
本季最大获利了结 / 清仓标的
XBI
前期市值: US$1.8亿
在 Q1 2026 季度中，Affinity Asset Advisors, LLC 共进行了 97 项持仓异动，包含新建仓 26 个仓位、加仓 31 个仓位、减仓 25 个仓位以及清仓 15 个仓位。 其中最大新建仓标的为 SPY。 本季清仓仓位包含 XBI。
本页面所有持股数据均直接同步自美国证券交易委员会（SEC）EDGAR 官方系统之 13F-HR / 13F-HR/A 季度申报文件。AlphaSMO 通过机器解析 CUSIP 与个股对照，提供 100% 精准对齐的历史时序数据集，并支持 Schema.org 结构化数据格式。
解析公司高管、董事与 10% 大股东之 Form 4 内部人交易申报，掌握高管自家股票买卖第一手信号。
深入剖析 5% 股权申报门槛、13D 与 13G 之差异，以及最新 SEC 申报时程规范，洞察机构法人的激进投资动向。